Zacks Investment Research upgraded shares of Hoth Therapeutics (NASDAQ:HOTH) from a hold rating to a buy rating in a research note released on Wednesday, Zacks.com reports. They currently have $1.50 price target on the stock.
According to Zacks, “Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company’s BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is based in New York, United States. “
Shares of Hoth Therapeutics stock opened at $1.24 on Wednesday. Hoth Therapeutics has a 52-week low of $1.14 and a 52-week high of $3.50. The company has a 50 day moving average of $1.32 and a 200 day moving average of $1.56. The company has a market capitalization of $29.60 million, a P/E ratio of -2.14 and a beta of 1.06.
About Hoth Therapeutics
Hoth Therapeutics, Inc engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema.
Featured Story: Momentum Indicators
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.